FDA reports increased risk of immune thrombocytopenia after J&J vaccine

The Food and Drug Administration has revised its and fact sheets for the Johnson & Johnson COVID-19 vaccine due to reports of immune thrombocytopenia (ITP), a disorder that can cause easy or excessive bruising and bleeding due to very low platelet levels. According to the recipient fact sheet, the chance of ITP is 鈥渧ery low,鈥 with symptoms in most cases occurring within 42 days after vaccination. FDA it continues to monitor the level of potential excess risk with the Centers for Disease Control and Prevention. Individuals with a history of ITP should discuss the risk with their health care provider and the potential need for platelet monitoring after vaccination, the fact sheets note.
Related News Articles
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.鈥檚 nomination for secretary of the Department of Health and Human Services. A鈥
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the鈥
Headline
CDC recommends two doses of COVID-19 vaccine for older individuals, lowers pneumococcal vaccine age聽
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to鈥
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition鈥
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their鈥
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers鈥